Skip to main content
CivicGate

S 3134
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

Combating Counterfeit Pharmaceuticals Act of 2025

To amend the Fentanyl Sanctions Act to address trafficking of copy-cat and counterfeit drugs and active pharmaceutical ingredients, and for other purposes.

Introduced Nov 6, 2025

Latest action (Nov 6, 2025) Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.

Policy area
Issues
Foreign Policy

Summary

This bill amends the Fentanyl Sanctions Act to expand its scope from opioids to broader illicit drugs, including counterfeit drugs and copy-cat ingredients. It defines copy-cat ingredients as substances designed to mimic approved prescription drugs but manufactured using different processes or with lower quality standards. The bill allows the Director of National Intelligence to delegate certain authorities and adds counterfeit drugs and copy-cat ingredients to activities that can trigger sanctions. It also modifies waiver provisions to include medications on the federal drug shortage list and makes technical changes throughout the act to reflect the expanded focus on illicit drugs beyond opioids.

AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.

Sponsor (1)

Money behind the sponsor

Top reported contributors to Tom Cotton’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.

  • NULL $80,461
  • APOLLO MANAGEMENT $25,600
  • APOLLO GLOBAL MANAGEMENT $19,800
  • BRODIE GENERATIONAL CAPITAL PARTNERS $13,200
  • APOLLO $11,600

Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Tom Cotton → · Outside spending →

Actions (2)

  1. Nov 6, 2025 Read twice and referred to the Committee on Banking, Housing, and Urban Affairs. · senate
  2. Nov 6, 2025 Introduced in Senate

Similar bills (6)

Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.

Full text

IN THE SENATE OF THE UNITED STATES

November 6, 2025

Mr. Cotton (for himself and Mr. Ricketts) introduced the following bill; which was read twice and referred to the Committee on Banking, Housing, and Urban Affairs

A BILL

To amend the Fentanyl Sanctions Act to address trafficking of copy-cat and counterfeit drugs and active pharmaceutical ingredients, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Combating Counterfeit Pharmaceuticals Act of 2025”.

SEC. 2. DEFINITIONS.

Section 7203 of the Fentanyl Sanctions Act (21 U.S.C. 2302) is amended—

(1) by redesignating paragraphs (4) through (10) as paragraphs (5) through (11), respectively;

(2) by inserting after paragraph (3) the following:

“(4) Copy-cat ingredient.—The term ‘copy-cat ingredient’, with respect to a drug, means an ingredient that is intended, including through the container or labeling of the ingredient, to mimic, knockoff, or otherwise purports to be a drug substance that is a component of a prescription drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or licensed under section 351 of the Public Health Service Act (42 U.S.C. 262), and—

“(A) the ingredient is manufactured by a different process than specified for the drug substance in the approval or licensure of the drug; or

“(B) the purity or quality of the ingredient falls below that of the drug substance that is a component of the approved or licensed drug.

“(5) Counterfeit drug.—The term ‘counterfeit drug’ has the meaning given that term in section 201(g)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(g)(2)).”;

(3) in paragraph (6), as redesignated by paragraph (1)—

(A) in the paragraph heading, by striking “opioid” and inserting “illicit drug”; and

(B) by striking “opioid” each place it appears and inserting “illicit drug”; and

(4) by striking paragraph (9), as so redesignated—

(A) in the paragraph heading, by striking “Opioid” and inserting “Illicit drug”;

(B) in the matter preceding subparagraph (A), by striking “opioid” and inserting “illicit drug”; and

(C) in subparagraph (A)—

(i) in clause (i), by striking “; or” and inserting a semicolon; and

(ii) by adding at the end the following:

“(iii) counterfeit drugs; or

“(iv) copy-cat ingredients;”.

SEC. 3. MODIFICATION OF REQUIREMENTS FOR DIRECTOR OF NATIONAL INTELLIGENCE.

(a) Authority To Delegate.—

(1) Identification of foreign drug traffickers.—Section 7211 of the Fentanyl Sanctions Act (21 U.S.C. 2311) is amended, in subsections (d) and (e), by inserting “(or a designee of the Director)” after “Director of National Intelligence” each place it appears.

(2) Briefings on implementation.—Section 7216 of the Fentanyl Sanctions Act (21 U.S.C. 2316) is amended by inserting “(or a designee of the Director)” after “Director of National Intelligence”.

(b) Program on Use of Intelligence Resources.—Section 7231 of the Fentanyl Sanctions Act (21 U.S.C. 2331) is amended—

(1) in the section heading, by striking “opioid” and inserting “illicit drug”;

(2) in subsection (a)—

(A) in paragraph (1), by striking “, in consultation” and all that follows through “Policy,”; and

(B) in paragraph (2)(A), by striking “narcotics” and inserting “illicit drug”;

(3) by striking subsections (b) and (c); and

(4) by redesignating subsection (d) as subsection (b).

SEC. 4. WAIVER FOR ACCESS TO PRESCRIPTION MEDICATIONS.

Section 7214(b)(1)(B) of the Fentanyl Sanctions Act (21 U.S.C. 2314(b)(1)(B)) is amended by inserting after “medications” the following: “on the current drug shortage list maintained by the Secretary of Health and Human Services under section 506E of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356e)”.

SEC. 5. TECHNICAL AND CONFORMING AMENDMENTS.

(a) Fentanyl Sanctions Act.—The Fentanyl Sanctions Act (21 U.S.C. 2301 et seq.) is amended—

(1) in section 7202(3) (21 U.S.C. 2301(3)), by inserting “and other illicit drugs” after “fentanyl”;

(2) in the subtitle heading for subtitle A, by striking “Opioid” and inserting “Illicit Drug”;

(3) in section 7211 (21 U.S.C. 2311), in the section heading, by striking “opioid” and inserting “illicit drug”;

(4) in section 7214 (21 U.S.C. 2314)—

(A) in subsection (a)(2)(B)(ii), by striking “opioids” and inserting “illicit drugs”; and

(B) in subsection (b)(2), by striking “illicit opioids” and inserting “illicit drugs”;

(5) in section 7217(a) (Public Law 116-91; 133 Stat. 2269), in the matter preceding paragraph (1), by striking “illicit opioids” and inserting “illicit drugs”;

(6) in section 7233 (21 U.S.C. 2333), by striking “section 7203(8)” and inserting “section 7203(9)”;

(7) by striking “opioid trafficking” each place it appears and inserting “illicit drug trafficking”;

(8) by striking “illicit opioids” each place it appears and inserting “illicit drugs”;

(9) by striking “foreign opioid traffickers” each place it appears and inserting “foreign illicit drug traffickers”; and

(10) by striking “foreign opioid trafficker” each place it appears and inserting “foreign illicit drug trafficker”.

(b) International Narcotics Control Strategy Report.—Section 489(a)(9) of the Foreign Assistance Act of 1961 (22 U.S.C. 2291h(a)(9)) is amended—

(1) in subparagraph (A), by inserting “(or a designee of the Director)” after “Director of National Intelligence”; and

(2) by striking “illicit opioids” each place it appears and inserting “illicit drugs”. <all>

Comments

Comments

Loading comments…